{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T17:40:20Z","timestamp":1772127620620,"version":"3.50.1"},"reference-count":50,"publisher":"Informa UK Limited","issue":"3","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Int. J. Hematol. Oncol."],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.2217\/ijh-2021-0004","type":"journal-article","created":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T20:27:11Z","timestamp":1715977631000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":7,"title":["A Phase I Trial of Talazoparib in Patients with Advanced Hematologic Malignancies"],"prefix":"10.2217","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3023-6834","authenticated-orcid":false,"given":"Ajay K","family":"Gopal","sequence":"first","affiliation":[{"name":"Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rakesh","family":"Popat","sequence":"additional","affiliation":[{"name":"National Institute for Health Research University College London Hospitals Clinical Research Facility, University College London Hospitals NHS Foundation Trust, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8574-8365","authenticated-orcid":false,"given":"Ryan J","family":"Mattison","sequence":"additional","affiliation":[{"name":"Carbone Cancer Center, University of Wisconsin, Madison, WI, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobias","family":"Menne","sequence":"additional","affiliation":[{"name":"Department of Hematology, Freeman Hospital, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian","family":"Bloor","sequence":"additional","affiliation":[{"name":"The Christie NHS Foundation Trust, University of Manchester, Manchester, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terry","family":"Gaymes","sequence":"additional","affiliation":[{"name":"Department of Biomolecular Science, Kingston University, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6834-5625","authenticated-orcid":false,"given":"Asim","family":"Khwaja","sequence":"additional","affiliation":[{"name":"University College London Cancer Institute & University College London Hospitals NHS Foundation Trust, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2074-5678","authenticated-orcid":false,"given":"Mark","family":"Juckett","sequence":"additional","affiliation":[{"name":"Carbone Cancer Center, University of Wisconsin, Madison, WI, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Chen","sequence":"additional","affiliation":[{"name":"Pfizer Inc., New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew J","family":"Cotter","sequence":"additional","affiliation":[{"name":"Pfizer Inc., New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ghulam J","family":"Mufti","sequence":"additional","affiliation":[{"name":"Department of Hematology, King\u2019s College London, King\u2019s College Hospital NHS Foundation Trust, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2021,10,23]]},"reference":[{"key":"e_1_3_6_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl443"},{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.2706"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aam7344"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-7-152"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-018-0055-6"},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1407390"},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2016.06.008"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2018.05.013"},{"key":"e_1_3_6_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2016-204269"},{"key":"e_1_3_6_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10086"},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2175"},{"issue":"6","key":"e_1_3_6_13_1","first-page":"2333","article-title":"Gene mutation profile and risk stratification in AML1-ETO-positive acute myeloid leukemia based on next-generation sequencing","volume":"42","author":"Yu G","year":"2019","unstructured":"YuG, YinC, WuFet al. Gene mutation profile and risk stratification in AML1-ETO-positive acute myeloid leukemia based on next-generation sequencing. Oncol. Rep. 42(6), 2333\u20132344 (2019).","journal-title":"Oncol. Rep."},{"key":"e_1_3_6_14_1","doi-asserted-by":"publisher","DOI":"10.1159\/000497209"},{"key":"e_1_3_6_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-01-265769"},{"key":"e_1_3_6_16_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-09-0872"},{"key":"e_1_3_6_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00210-6"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.6287"},{"key":"e_1_3_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2013.12.019"},{"key":"e_1_3_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2014.12.001"},{"key":"e_1_3_6_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1802905"},{"key":"e_1_3_6_22_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1891"},{"key":"e_1_3_6_23_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-16-1250"},{"key":"e_1_3_6_24_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-13-0803"},{"key":"e_1_3_6_25_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aax6367"},{"key":"e_1_3_6_26_1","unstructured":"European Medicines Agency. TALZENNA \u00ae (talazoparib) Summary of product characteristics (2019). www.ema.europa.eu\/en\/documents\/product-information\/talzenna-epar-product-information_en.pdf"},{"key":"e_1_3_6_27_1","unstructured":"Pfizer Inc. TALZENNA \u00ae (talazoparib) prescribing information (2020). http:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=11046"},{"issue":"6","key":"e_1_3_6_28_1","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1200\/JCO.2020.38.6_suppl.119","article-title":"TALAPRO-1: A phase II study of talazoparib (TALA) in men with DNA damage repair mutations (DDRmut) and metastatic castration-resistant prostate cancer (mCRPC):first interim analysis (IA)","volume":"38","author":"De Bono J","year":"2020","unstructured":"DeBono J, MehraN, HiganoCSet al. TALAPRO-1: A phase II study of talazoparib (TALA) in men with DNA damage repair mutations (DDRmut) and metastatic castration-resistant prostate cancer (mCRPC):first interim analysis (IA). J. Clin. Oncol. 38(Suppl. 6), 119\u2013119 (2020).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_6_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.5076"},{"key":"e_1_3_6_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/89.15.1138"},{"key":"e_1_3_6_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-07-235358"},{"key":"e_1_3_6_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-10-4149"},{"issue":"12","key":"e_1_3_6_33_1","first-page":"3671","article-title":"Report of an international working group to standardize response criteria for myelodysplastic syndromes","volume":"96","author":"Cheson BD","year":"2000","unstructured":"ChesonBD, BennettJM, KantarjianHet al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 96(12), 3671\u20133674 (2000).","journal-title":"Blood"},{"key":"e_1_3_6_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-093906"},{"key":"e_1_3_6_35_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"e_1_3_6_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1520"},{"key":"e_1_3_6_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14793"},{"key":"e_1_3_6_38_1","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_238473"},{"key":"e_1_3_6_39_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00570"},{"key":"e_1_3_6_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-04-778225"},{"key":"e_1_3_6_41_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-02-734541"},{"key":"e_1_3_6_42_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00914-1"},{"key":"e_1_3_6_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2019.08.020"},{"key":"e_1_3_6_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-017-2300-7"},{"key":"e_1_3_6_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2014.04.016"},{"key":"e_1_3_6_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gde.2016.03.011"},{"key":"e_1_3_6_47_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.5"},{"key":"e_1_3_6_48_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.183160"},{"key":"e_1_3_6_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2020.100696"},{"key":"e_1_3_6_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2016.03.007"},{"key":"e_1_3_6_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30360-4"}],"container-title":["International Journal of Hematologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/ijh-2021-0004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T20:27:19Z","timestamp":1715977639000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/ijh-2021-0004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["10.2217\/ijh-2021-0004"],"URL":"https:\/\/doi.org\/10.2217\/ijh-2021-0004","relation":{},"ISSN":["2045-1393","2045-1407"],"issn-type":[{"value":"2045-1393","type":"print"},{"value":"2045-1407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iijh20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iijh20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-04-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-30","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"IJH35"}}